سعر كلوجراستات 12.5 مجم/50 مل محلول للتسريب الوريدي 2022

Clograstat 12.5mg/50ml i.v.infusion: Tirofiban (Global Pharmaceutical Industries).

• Reduce thrombotic cardiovascular events in NSTE-ACS (US AGGRASTAT tirofiban IV labeling).Population: See labelDailyMed (U.S. National Library of Medicine)

• Bleeding most common; thrombocytopenia; edema, bradycardia, dizziness reported.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Severe hypersensitivity to tirofiban; history of thrombocytopenia with prior tirofiban; active internal bleeding or bleeding diathesis / major surgery or severe trauma within prior month.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Serious bleeding risk (especially access-site); monitor platelets ~6 h after start and daily — discontinue with heparin if thrombocytopenia confirmed. Reduce maintenance dose if CrCl ≤60 mL/min.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Available case reports have not established association with major birth defects; untreated MI is a pregnancy emergency. Animal studies without fetal harm at studied multiples of human dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Tirofiban: Reversible antagonist of fibrinogen binding to the platelet GP IIb/IIIa receptor, inhibiting platelet aggregation (US AGGRASTAT label).